--- title: Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine nct_id: NCT03933098 overall_status: UNKNOWN phase: PHASE3 sponsor: International Vaccine Institute study_type: INTERVENTIONAL primary_condition: Typhoid countries: Nepal canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03933098.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03933098" ct_last_update_post_date: 2020-04-22 last_seen_at: "2026-05-12T06:37:34.485Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine **Official Title:** A Phase III Multicenter, Observer-Blinded, Randomized, Active Controlled, Immune Non-inferiority and Safety Study of Vi-DT Vaccine Compared to Typbar TCV® in Healthy 6 Months-45 Years Aged Nepalese Participants. **NCT ID:** [NCT03933098](https://clinicaltrials.gov/study/NCT03933098) ## Key Facts - **Status:** UNKNOWN - **Phase:** PHASE3 - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 1800 - **Lead Sponsor:** International Vaccine Institute - **Collaborators:** SK Bioscience Co., Ltd. - **Conditions:** Typhoid - **Start Date:** 2019-11-15 - **Completion Date:** 2021-01 - **CT.gov Last Update:** 2020-04-22 ## Brief Summary This is a Multicenter, observer-blinded, randomized, Active controlled, Phase 3 study in healthy 6 months to 45 years aged Nepalese at the time of the first vaccine dose. The study objectives are: I. Demonstrate non-inferiority of Vi-DT compared to Typbar TCV® as measured by seroconversion rates of anti-Vi IgG ELISA antibody titers, 4 weeks after single dose (pooled immunogenicity of three lots of Vi-DT) II. Demonstrate the equivalence of immunogenicity as measured by anti-Vi IgG GMT of three lots of Vi-DT vaccine 4 weeks after single dose. ## Detailed Description Subjects will be stratified according to age. The study procedure is as follows: Visit 1 (day-1 to -7): Screen participants by medical/medications history, physical examination, Vital signs, Urine pregnancy test (UPT) Visit 2 (day 0): Enroll, randomize and administer vaccine to eligible participants and assess participant safety by physical examination and Vital signs, Collect blood for immunogenicity assessments. Visit 3 (day 7): Check solicited adverse reaction 7 days post vaccination and Assess participant safety by physical examination and Vital signs Visit 4 (day 28): Assess participant safety by physical examination and Vital signs, Collect blood for immunogenicity assessments Visit 5 (day 84): Assess participant safety by physical examination and Vital signs Visit 6 (day 168): Assess participant safety by physical examination and Vital signs, Collect blood for immunogenicity assessments, and fill in study completion form in the absence of any safety concern. This study is observer-blind: vaccine administrator and vaccine safety evaluator will be two distinct persons to avoid bias of safety assessment. Trial staff other than the vaccine administrator. For retention: After vaccination, field health worker/designee will contact participant every day till Day 7 by physical visit or by phone call. Follow-up reminder calls will be done very frequently as per discretion of study staff until 24 weeks for all participant to assess participant safety. ## Eligibility - **Minimum age:** 6 Months - **Maximum age:** 45 Years - **Sex:** ALL - **Healthy Volunteers:** Yes ``` Inclusion Criteria: 1. Healthy participants 6 months to 45 years of age at enrollment 2. Participants/Parents/LAR who have voluntarily given informed consent/assent 3. Participants/Parents/LAR willing to follow the study procedures of the study and available for the entire duration of the study Exclusion Criteria: 1. Child with a congenital abnormality 2. Subject concomitantly enrolled or scheduled to be enrolled in another trial 3. Known history of immune function disorders including immunodeficiency diseases (Known HIV infection or other immune function disorders) 4. Chronic use of systemic steroids (\>2 mg/kg/day or \>20 mg/day prednisone equivalent for periods exceeding 10 days), cytotoxic or other immunosuppressive drugs 5. Receipt of blood or blood-derived products in the past 3 months 6. Subject with a previously ascertained or suspected disease caused by S. Typhi 7. Subject who have had household contact with/and or intimate exposure to an individual with laboratory-confirmed S. Typhi 8. Individual who has previously received a typhoid vaccine 9. Subject who has received or is expected to receive other vaccines from 1 month prior to IP vaccination to Visit 4 (approx.1 month post IP) except PVC booster as per EPI schedule 10. Known history or allergy to vaccines or other medications 11. History of uncontrolled coagulopathy or blood disorders 12. Any abnormality or chronic disease which in the opinion of the investigator might be detrimental for the safety of the subject and interfere with the assessment of the study objectives 13. Any female participant who is lactating, pregnant\* or planning for pregnancy during the course of study period 14. Participants/Parents/LAR planning to move from the study area before the end of study period 15. As per Investigator's medical judgement individuals could be excluded from the study inspite of meeting all inclusion/exclusion criteria mentioned above Temporary Contraindication 16. Acute illness, in particular infectious disease or fever (axillary temperature ≥37.5°C), within three days prior to enrolment and vaccination. * Urine pregnancy test (UPT) will be performed in all married females prior to injection ``` ## Arms - **Test group A: Lot 1 Vi-DT (typhoid conjugate vaccine)** (EXPERIMENTAL) — One dose of Vi-DT (typhoid conjugate vaccine) Lot 1 will be administrated intramuscularly at Enrollment visit (Day 0). MR for age group at 9-15 months. - **Test group B: Lot 2 Vi-DT (typhoid conjugate vaccine)** (EXPERIMENTAL) — One dose of Vi-DT (typhoid conjugate vaccine) Lot 2 will be administrated intramuscularly at Enrollment visit (Day 0). MR for age group at 9-15 months. - **Test group C: Lot 3 Vi-DT (typhoid conjugate vaccine)** (EXPERIMENTAL) — One dose of Vi-DT (typhoid conjugate vaccine) Lot 3 will be administrated intramuscularly at Enrollment visit (Day 0). MR for age group at 9-15 months. - **Test group D: Typbar TCV** (ACTIVE_COMPARATOR) — One dose of Typbar TCV will be administrated intramuscularly at Enrollment visit (Day 0). MR for age group at 9-15 months. ## Interventions - **Test Vaccine Vi-DT Typhoid conjugate** (BIOLOGICAL) — * Manufacturer: SK Bioscience Co., Ltd. * Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid * Dose: 25 µg of Vi polysaccharide/0.5 mL, presented in 3 mL multi-dose glass vial - **Control Vaccine Typbar TCV®** (BIOLOGICAL) — * Manufacturer: Bharat Biotech * Ingredient: Purified Vi capsular polysaccharide of Salmonella Ty2 conjugated to tetanus toxoid protein * Dose: 0.5 ml ## Primary Outcomes - **Seroconversion rate1** _(time frame: 4 weeks (28 days) after vaccination of Vi-DT(pooled)/ Typbar TCV® compared to baseline (D0))_ — Defined as a 4-fold increase of serum anti-Vi IgG antibody titer - **Geometric Mean Titers (GMT)1** _(time frame: 4 weeks after vaccination of Vi-DT)_ — Measurement of the Geometric Mean Titers (GMT) following 4 weeks after vaccination of three lots of Vi-DT ## Secondary Outcomes - **Geometric Mean Titers (GMT) 2** _(time frame: 4 weeks and 24 weeks after vaccination of Vi-DT(pooled)/ Typbar TCV®)_ - **Seroconversion rate 2** _(time frame: 24 weeks (168 days) after vaccination of Vi-DT(pooled)/ Typbar TCV® compared to baseline (D0).)_ - **Seroconversion rate 3** _(time frame: 4 weeks (28 days) after vaccination of Vi-DT(pooled))_ - **Seroconversion rate 4** _(time frame: 4 weeks (28 days) after vaccination of Vi-DT(pooled))_ - **Seroconversion rate 5** _(time frame: 4 weeks (28 days) after vaccination of MR compared to baseline (D0))_ - **Safety endpoints for solicited adverse events (reactogenicity)** _(time frame: 7days after vaccination of Vi-DT(pooled)/ Typbar TCV®)_ ## Locations (4) - Nepalgunj medical college, Bānke, City- Nepalgunj, Nepal - B.P.Koirala Institute of Health Sciences, Rautahat, Dharan, Nepal - Dhulikhel Hospital, Kavre, Dhulikhel, Nepal - Kanti Children's Hospital, Kathmandu, Sukedhara, Nepal ## Recent Field Changes (last 30 days) - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.maxAge` — added _(2026-05-12)_ - `outcomes.secondary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `sponsor.collaborators` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.nepalgunj medical college|bānke|city- nepalgunj|nepal` — added _(2026-05-12)_ - `locations.b.p.koirala institute of health sciences|rautahat|dharan|nepal` — added _(2026-05-12)_ - `locations.dhulikhel hospital|kavre|dhulikhel|nepal` — added _(2026-05-12)_ - `locations.kanti children's hospital|kathmandu|sukedhara|nepal` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT03933098.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT03933098* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*